Mobile

A Study of Patients Previously Enrolled in Study GA29350 to Evaluate the Long-Term Safety and Efficacy of GDC-0853 in Patients with Moderate to Severe Rheumatoid Arthritis

Mise à jour : Il y a 4 ans
Référence : EUCTR2016-000498-19

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

• To evaluate the long-term safety of GDC-0853 over an extended treatment period of up to 52 weeks • To evaluate the efficacy of GDC-0853 (analysed separately for methotrexate-inadequate response [MTX-IR] and tumour necrosis factor-inadequate response [TNF-IR] patients) at Week 52 relative to baseline in Study GA29350

Critère d'inclusion

  • Rheumatoid Arthritis

Liens